OGT’s ASHG 2013 workshop highlights the need for comprehensive genomic analysis
Oxford, UK – 19 November 2013. Oxford Gene Technology (OGT), provider of innovative genetics research and biomarker solutions to advance molecular medicine, has made a recording of its recent American Society of Human Genetics (ASHG) workshop available to watch online. The oversubscribed workshop, titled “Complementing next generation sequencing experiments with high-resolution copy number variation detection”, was recorded at the meeting in Boston (US) on the 25th of October 2013.
Over 120 attendees heard Professor Madhuri Hegde, Professor of Human Genetics at Emory University School of Medicine and OGT’s Chief Executive, Dr Mike Evans discuss the need for comprehensive and complementary genomic testing for reliable results. The workshop described how OGT’s CytoSure Molecular Testing Arrays are being used alongside next generation sequencing (NGS) to deliver accurate detection of point mutations and single exon copy number aberrations in a clinical genetics research laboratory. Professor Hegde presented numerous compelling case studies in which the comparative genomic hybridisation arrays accurately identified mutations that were missed by NGS alone.
OGT has worked in close collaboration with Emory Genetics Laboratory to develop arrays for use in the detection of complex disorders, which are available as part of OGT’s CytoSure range of products.
View the workshop here.
For more information on OGT’s products and services, please visit www.ogt.com.
About Oxford Gene Technology
Founded by Professor Ed Southern, Oxford Gene Technology (OGT) provides innovative genetics research and biomarker solutions to advance molecular medicine. The company has two trading businesses: Genomics comprises of CytoSure™ cytogenetics array, labelling and interpretation software products and services for the detection of chromosomal abnormalities, and Genefficiency™ Genomic Services, a unique combination of platforms, expertise and processing capabilities to deliver rapid, relevant genomic data. The Biomarkers business utilises proprietary next generation technologies to build a rich patent-protected portfolio of promising biomarkers for early stage cancer detection including advanced programmes in colorectal and prostate cancer plus the autoimmune disease systemic lupus erythematosus.
CytoSure™ and Genefficiency™ NGS browser/report: For Research Use Only; Not for Use in Diagnostic Procedures
CytoSure: This product is provided under an agreement between Agilent Technologies, Inc., and OGT. The manufacture, use, sale or import of this product may be subject to one or more of U.S. patents, pending applications, and corresponding international equivalents, owned by Agilent Technologies, Inc. The purchaser has the non-transferable right to use and consume the product for RESEARCH USE ONLY AND NOT for DIAGNOSTICS PROCEDURES. It is not intended for use, and should not be used, for the diagnosis, prevention, monitoring, treatment or alleviation of any disease or condition, or for the investigation of any physiological process, in any identifiable human, or for any other medical purpose.
For further information, please contact:
Oxford Gene Technology, Begbroke Science Park, Begbroke Hill
Woodstock Road, Begbroke, Oxfordshire, OX5 1PF, U.K.
T: +44 (0) 1865 856826 ; F: +44 (0) 1865 848684
E: [email protected]
W: www.ogt.com ; Twitter: @OxfordGeneTech
Oxford Gene Technology - OGT
Stephen Archibald: Director of Communications
t: +44 (0)1865 856828
e: [email protected]